We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
+$46.9M
Cap. Flow %
3.47%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 10.46%
3 Consumer Staples 0.55%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
$378K 0.03%
30,000
– –
AKAO
102
DELISTED
Achaogen Inc
AKAO
$344K 0.03%
60,000
– –
APYX icon
103
Apyx Medical
APYX
$125M
$342K 0.03%
162,700
– –
ARIA
104
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$313K 0.02%
50,000
-400,000
-89% -$2.63M
ARMP icon
105
Armata Pharmaceuticals
ARMP
$164M
$298K 0.02%
534
-37
-6% -$28.3K
TNDM icon
106
Tandem Diabetes Care
TNDM
$1.13B
$295K 0.02%
+2,500
New +$248K
CRIS icon
107
Curis
CRIS
$2.74M
$291K 0.02%
50
– –
CRL icon
108
Charles River Laboratories
CRL
$13B
$274K 0.02%
+3,410
New +$246K
HNT
109
DELISTED
HEALTH NET INC
HNT
$262K 0.02%
3,831
– –
GTS
110
DELISTED
Triple-S Management Corporation
GTS
$254K 0.02%
11,147
– –
GILD icon
111
Gilead Sciences
GILD
$181B
$249K 0.02%
2,457
– –
PMC
112
DELISTED
PharMerica Corporation
PMC
$238K 0.02%
6,800
– –
MCK icon
113
McKesson
MCK
$105B
$233K 0.02%
+1,179
New +$223K
ITGR icon
114
Integer Holdings
ITGR
$4.29B
$231K 0.02%
4,817
– –
TARO
115
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$231K 0.02%
1,493
– –
CRVL icon
116
CorVel
CRVL
$3.62B
$225K 0.02%
+15,345
New +$189K
CBM
117
DELISTED
Cambrex Corporation
CBM
$221K 0.02%
4,692
– –
COR icon
118
Cencora
COR
$61.7B
$211K 0.02%
+2,030
New +$199K
THC icon
119
Tenet Healthcare
THC
$21B
$210K 0.02%
+6,927
New +$227K
LPNT
120
DELISTED
LifePoint Health, Inc.
LPNT
$210K 0.02%
2,862
+340
+13% +$24.2K
MGLN
121
DELISTED
Magellan Health Services, Inc.
MGLN
$207K 0.02%
3,351
-59
-2% -$3.17K
WOOF
122
DELISTED
VCA Inc.
WOOF
$205K 0.02%
+3,731
New +$205K
SCAI
123
DELISTED
Surgical Care Affiliates, Inc.
SCAI
$204K 0.02%
+5,133
New +$179K
BIIB icon
124
Biogen
BIIB
$31.9B
$199K 0.01%
+648
New +$186K
ENSG icon
125
The Ensign Group
ENSG
$10.1B
$198K 0.01%
+9,347
New +$197K
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $46.9M of net new capital in Q4 2015, opening 40 new positions and adding to 30 existing holdings. Its largest new stake was Allergan plc: 145,000 shares worth $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $22.7M trimmed.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.